Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C20H23NO.ClH |
| Molecular Weight | 329.864 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.OC(C1CN2CCC1CC2)(C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChIKey=MVCBFPDJWSQMNY-UHFFFAOYSA-N
InChI=1S/C20H23NO.ClH/c22-20(17-7-3-1-4-8-17,18-9-5-2-6-10-18)19-15-21-13-11-16(19)12-14-21;/h1-10,16,19,22H,11-15H2;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C20H23NO |
| Molecular Weight | 293.4027 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Quifenadine is an antihistaminic agent.
Quifenadine both blocks histamine H1-receptors in the peripheral tissues, and activates enzyme diaminoxidase (histaminase), due to this decreasing the histamine concentration in tissues.
It is indicated in cases of pollinosis, acute and chronic urticaria, seasonal rhinitis (hay fever), allergic rhinitis, allergic conjunctivitis, angioneurotic Quinqe’s edema, dermatosis (eczema, neurodermatitis, pruritus etc.), allergic reactions caused by food or medicines. Quifanidine exhibits antiarrhythmic activity in children with frequent premature beats, without significant QT prolongation, or sinus node depression.
Approval Year
Sample Use Guides
For adults: single dose is 25-50 mg 2-4 times a day. Maximum daily dose is 200 mg.
For children older than 12 years - 25 mg 2-3 times a day.
The duration of the course of treatment is 10-20 days. If it is necessary, the course of treatment may be repeated.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:08:36 GMT 2025
by
admin
on
Mon Mar 31 22:08:36 GMT 2025
|
| Record UNII |
6WSK4828LL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6WSK4828LL
Created by
admin on Mon Mar 31 22:08:36 GMT 2025 , Edited by admin on Mon Mar 31 22:08:36 GMT 2025
|
PRIMARY | |||
|
SUB128777
Created by
admin on Mon Mar 31 22:08:36 GMT 2025 , Edited by admin on Mon Mar 31 22:08:36 GMT 2025
|
PRIMARY | |||
|
DTXSID30908989
Created by
admin on Mon Mar 31 22:08:36 GMT 2025 , Edited by admin on Mon Mar 31 22:08:36 GMT 2025
|
PRIMARY | |||
|
115027
Created by
admin on Mon Mar 31 22:08:36 GMT 2025 , Edited by admin on Mon Mar 31 22:08:36 GMT 2025
|
PRIMARY | |||
|
100000154970
Created by
admin on Mon Mar 31 22:08:36 GMT 2025 , Edited by admin on Mon Mar 31 22:08:36 GMT 2025
|
PRIMARY | |||
|
10447-38-8
Created by
admin on Mon Mar 31 22:08:36 GMT 2025 , Edited by admin on Mon Mar 31 22:08:36 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |